{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Tozasertib_Lactate",
  "nciThesaurus": {
    "casRegistry": "899827-04-4",
    "chebiId": "",
    "chemicalFormula": "C23H28N8OS.C3H6O3",
    "definition": "The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis.",
    "fdaUniiCode": "CN8EF9N084",
    "identifier": "C61319",
    "preferredName": "Tozasertib Lactate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C62556"
    ],
    "synonyms": [
      "Aurora Kinase Inhibitor MK-0457",
      "L-001281814",
      "MK-0457",
      "Propanoic acid, 2-hydroxy-, (2S)-, compd. with N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)cyclopropanecarboxamide",
      "TOZASERTIB LACTATE",
      "Tozasertib Lactate",
      "VX-680"
    ]
  }
}